基于网络药理学方法揭示黄芪丹参复方治疗妊娠高血压综合征的药理机制。
Uncovering the Pharmacological Mechanism of Astragalus Salvia Compound on Pregnancy-Induced Hypertension Syndrome by a Network Pharmacology Approach.
机构信息
Hunan University of Chinese Medicine, Changsha, 410208, Hunan Province, China.
出版信息
Sci Rep. 2017 Dec 4;7(1):16849. doi: 10.1038/s41598-017-17139-x.
To uncover the pharmacological mechanism of Astragalus Salvia compound (ASC) on pregnancy-induced hypertension syndrome (PIH), to provide useful information for clinical, as well as to connect the basic and clinical by a network pharmacological approach, we used network pharmacological approach. We collected ASC's compounds by traditional Chinese Medicine databases, and input them into PharmMapper to got their targets. Then we acquired PIH targets from Genecards and OMIM, collected the interactions of all the targets and other human proteins via String and INACT. We also constructed the network by Cytoscape and analyze it by MCODE so as to get clusters. Finally, we put all the targets of clusters into DAVID to do GO enrichment analysis. After these, four networks are constructed by Cytoscape; they are PIH network, compound-compound target network of ASC, ASC-PIH network, and compound target-PIH target-other human proteins' PPI network. According to the results, we think that ASC may directly regulate several biological processes and their genes in "endothelial cell activation and injury" and "placental or trophoblast cell ischemia" models to treat PIH. And it may indirectly act on the rest of the biological process to treat PIH or may not.
为了揭示黄芪丹参复方(ASC)治疗妊娠高血压综合征(PIH)的药理学机制,为临床提供有用的信息,并通过网络药理学方法将基础与临床联系起来,我们采用了网络药理学方法。我们通过中药数据库收集 ASC 的化合物,并将其输入 PharmMapper 以获得它们的靶点。然后我们从 Genecards 和 OMIM 获得 PIH 的靶点,通过 String 和 INACT 收集所有靶点与其他人类蛋白的相互作用。我们还通过 Cytoscape 构建网络,并通过 MCODE 进行分析以获得聚类。最后,我们将聚类的所有靶点都放入 DAVID 进行 GO 富集分析。经过这些步骤,我们通过 Cytoscape 构建了四个网络:PIH 网络、ASC 的化合物-化合物靶点网络、ASC-PIH 网络以及化合物靶点-PIH 靶点-其他人类蛋白的 PPI 网络。根据结果,我们认为 ASC 可能通过直接调节“血管内皮细胞激活和损伤”和“胎盘或滋养层细胞缺血”模型中的几个生物学过程及其基因来治疗 PIH。并且它可能通过间接作用于其余的生物学过程来治疗 PIH 或可能没有。
相似文献
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022-11-25
Evid Based Complement Alternat Med. 2016
Vasc Health Risk Manag. 2008
引用本文的文献
Evid Based Complement Alternat Med. 2022-9-22
Evid Based Complement Alternat Med. 2021-9-6
Evid Based Complement Alternat Med. 2021-8-2
本文引用的文献
Clin Exp Hypertens. 2016-1-28
Pharmacol Res. 2015-5-14
Nucleic Acids Res. 2015-1